Literature DB >> 2874822

Zopiclone produces effects on human performance similar to flurazepam, lormetazepam and triazolam.

A N Griffiths, D M Jones, A Richens.   

Abstract

The cognitive function and psychomotor performance of 10 healthy male volunteers were measured following single oral doses of: zopiclone (7.5 mg), flurazepam (15 mg), lormetazepam (1 mg), triazolam (0.25 mg) and placebo. The performance tests selected (stroop task, five choice serial reaction time, memory span, logical reasoning, mood and saccadic eye movement analysis) were thought to reflect aspects of normal daily activity. The tests demonstrated a clear reduction of performance for all active treatments. No drug emerged as the most potent sedative overall, as each of the tests was affected to a different degree by each drug. Drug effects were not qualitatively different between active treatments so that zopiclone was indistinguishable from the three benzodiazepines with which it was compared.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2874822      PMCID: PMC1400986          DOI: 10.1111/j.1365-2125.1986.tb05229.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

Review 1.  The Stroop color-word test: a review.

Authors:  A R Jensen; W D Rohwer
Journal:  Acta Psychol (Amst)       Date:  1966

2.  Saccadic eye movement analysis as a measure of drug effects on human psychomotor performance.

Authors:  A N Griffiths; R W Marshall; A Richens
Journal:  Br J Clin Pharmacol       Date:  1984       Impact factor: 4.335

3.  Pharmacokinetic and clinical observations on prolonged administration of flunitrazepam.

Authors:  E Wickstrøm; R Amrein; P Haefelfinger; D Hartmann
Journal:  Eur J Clin Pharmacol       Date:  1980       Impact factor: 2.953

4.  The relationship between peak velocity of saccadic eye movements and serum benzodiazepine concentration.

Authors:  P R Bittencourt; P Wade; A T Smith; A Richens
Journal:  Br J Clin Pharmacol       Date:  1981-10       Impact factor: 4.335

5.  Rate of entrance of benzodiazepines into the brain determined by eye movement recording.

Authors:  G Tedeschi; A T Smith; S Dhillon; A Richens
Journal:  Br J Clin Pharmacol       Date:  1983-01       Impact factor: 4.335

6.  Factor analytic and reliability studies on the Activation-Deactivation Adjective Check List.

Authors:  R E Thayer
Journal:  Psychol Rep       Date:  1978-06

7.  Anxiolytic cyclopyrrolones zopiclone and suriclone bind to a novel site linked allosterically to benzodiazepine receptors.

Authors:  R R Trifiletti; S H Snyder
Journal:  Mol Pharmacol       Date:  1984-11       Impact factor: 4.436

8.  A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane).

Authors:  G W Houghton; M J Dennis; R Templeton; B K Martin
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1985-02

9.  Sedative-hypnotics and human performance.

Authors:  L C Johnson; D A Chernik
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

  9 in total
  11 in total

1.  Actions of zopiclone and carbamazepine, alone and in combination, on human skilled performance in laboratory and clinical tests.

Authors:  T Kuitunen; M J Mattila; T Seppälä; K Aranko; M E Mattila
Journal:  Br J Clin Pharmacol       Date:  1990-09       Impact factor: 4.335

2.  Testing for benzodiazepine inebriation--relationship between benzodiazepine concentration and simple clinical tests for impairment in a sample of drugged drivers.

Authors:  Jørgen G Bramness; Svetlana Skurtveit; Jørg Mørland
Journal:  Eur J Clin Pharmacol       Date:  2003-09-20       Impact factor: 2.953

3.  Repeated dose effects of lormetazepam and flurazepam upon driving performance.

Authors:  K A Brookhuis; E R Volkerts; J F O'Hanlon
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

4.  Effects of oxazepam on eye movements and performance in vigilance tasks with static and dynamic stimuli.

Authors:  T H van Leeuwen; M N Verbaten; H S Koelega; G Camfferman; J van der Gugten; J L Slangen
Journal:  Psychopharmacology (Berl)       Date:  1994-02       Impact factor: 4.530

Review 5.  Comparative tolerability of newer agents for insomnia.

Authors:  Gary Zammit
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 6.  Zopiclone. A review of its pharmacological properties and therapeutic efficacy as an hypnotic.

Authors:  A N Wadworth; D McTavish
Journal:  Drugs Aging       Date:  1993 Sep-Oct       Impact factor: 3.923

7.  Interspecies Variation of In Vitro Stability and Metabolic Diversity of YZG-331, a Promising Sedative-Hypnotic Compound.

Authors:  Zhihao Liu; Yakun Yang; Li Sheng; Yan Li
Journal:  Front Pharmacol       Date:  2017-08-11       Impact factor: 5.810

8.  Loganin Exerts Sedative and Hypnotic Effects via Modulation of the Serotonergic System and GABAergic Neurons.

Authors:  Rui Shi; Yan Han; Yu Yan; Hao-Yi Qiao; Jun He; Wen-Wen Lian; Cong-Yuan Xia; Ting-Li Li; Wei-Ku Zhang; Jie-Kun Xu
Journal:  Front Pharmacol       Date:  2019-04-24       Impact factor: 5.810

9.  Eszopiclone: its use in the treatment of insomnia.

Authors:  Jaime M Monti; S R Pandi-Perumal
Journal:  Neuropsychiatr Dis Treat       Date:  2007-08       Impact factor: 2.570

10.  A computerized stroop test for the evaluation of psychotropic drugs in healthy participants.

Authors:  Raveendranadh Pilli; Mur Naidu; Usha Rani Pingali; J C Shobha; A Praveen Reddy
Journal:  Indian J Psychol Med       Date:  2013-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.